Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination

Keyphrases

• Homologous Recombination 100%
• Radiosensitization 100%
• Bladder Cancer 100%
• Imatinib 100%
• Knockdown 83%
• RAD51 83%
• Non-homologous End Joining 50%
• Radiotherapy 50%
• Lapatinib 33%
• Muscle-invasive Bladder Cancer 33%
• Cell Survival 16%
• Cell-free Extract 16%
• Drug Dosing 16%
• Patient Outcomes 16%
• Bladder Tumor 16%
• Concurrent Use 16%
• Recombination Protein 16%
• Tumor Phenotype 16%
• RNA Technology 16%
• Small Molecule Tyrosine Kinase Inhibitors 16%
• Radioresistance 16%
• Short Hairpin RNA (shRNA) 16%
• IC10 16%
• Pathway Selectivity 16%
• Vector Control 16%
• Treatment Modalities 16%
• Clonogenic Assay 16%
• Invasive Tumors 16%
• Treatment Failure 16%
• Muscle-invasive 16%

Biochemistry, Genetics and Molecular Biology

• Homologous Recombination 100%
• Imatinib 100%
• RAD51 83%
• Non-Homologous End Joining 50%
• Lapatinib 33%
• Cell Survival 16%
• Tyrosine Kinase Inhibitor 16%
• Small Molecule 16%
• Small Interfering RNA 16%
• Radiosensitivity 16%
• IC10 16%
• Small Hairpin RNA 16%
• Extract 16%
• Drug Dose 16%
• Clonogenic Assay 16%